Abstract
Ovarian cancer, a gynecological malignancy, is the most common cause of death in older women worldwide. The overall 5-year survival of ovarian cancer patients is only 20% because of late diagnosis, as well as distant metastasis and multidrug resistance. Therefore, predictive and prognostic markers are urgently required for the early diagnosis of ovarian cancer. CD147, an extracellular matrix metalloproteinase inducer, is overexpressed in ovarian cancers. Current knowledge suggests that CD147 is associated with the survival and progression of ovarian cancer, and is considered as a biomarker of poor outcome. Here, we specifically review the roles of CD147 in ovarian cancer progression and discuss the diagnostic and prognostic value of CD147 in patients with ovarian cancer. CD147 promotes ovarian cancer progression by its involvement in every facet of malignancy, including invasion, metastasis, survival, angiogenesis, and drug resistance. Although it is not fully confirmed, the combination of CD147 with other biomarkers might be of diagnostic value.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
